奈玛特韦/利托那韦治疗高危人群的 2019 冠状病毒病（COVID-19）后的反弹现象。
Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons.
机构信息
Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Clin Infect Dis. 2023 Feb 8;76(3):e537-e539. doi: 10.1093/cid/ciac481.
Abstract
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.
摘要
在一项纳入 483 例 COVID-19 高危患者接受奈玛特韦/利托那韦治疗的队列研究中，2 例患者（0.4%）在第 30 天前需要住院治疗。4 例患者（0.8%）在治疗后中位 9 天出现症状反弹，通常为轻度，所有患者均无需额外 COVID-19 靶向治疗而缓解。
相似文献
1
Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons.奈玛特韦/利托那韦治疗高危人群的 2019 冠状病毒病（COVID-19）后的反弹现象。
Clin Infect Dis. 2023 Feb 8;76(3):e537-e539. doi: 10.1093/cid/ciac481.
2
Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.奈玛特韦/利托那韦或莫努匹韦治疗后 COVID-19 反弹的临床特征：一项前瞻性队列研究。
Medicine (Baltimore). 2023 Sep 29;102(39):e35094. doi: 10.1097/MD.0000000000035094.
3
Nirmatrelvir-Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation.尼马瑞韦-利托那韦（奈玛特韦/利托那韦片）治疗妊娠期和哺乳期轻度 2019 冠状病毒病（COVID-19）。
Obstet Gynecol. 2023 May 1;141(5):957-960. doi: 10.1097/AOG.0000000000005152. Epub 2023 Mar 15.
4
Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19.COVID-19 患者使用奈玛特韦/利托那韦治疗后出现反弹现象导致的急性肺栓塞。
Am J Emerg Med. 2022 Nov;61:235.e5-235.e6. doi: 10.1016/j.ajem.2022.08.012. Epub 2022 Aug 6.
5
Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).新型冠状病毒病 2019（COVID-19）经奈玛特韦-利托那韦治疗后病毒学反弹的特征。
Clin Infect Dis. 2023 Feb 8;76(3):e526-e529. doi: 10.1093/cid/ciac512.
6
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.莫努匹韦和奈玛特韦-利托那韦：口服冠状病毒病 2019 抗病毒药物。
Clin Infect Dis. 2023 Jan 6;76(1):165-171. doi: 10.1093/cid/ciac180.
7
Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.新型冠状病毒病 2019 经奈玛特韦/利托那韦治疗后复发。
J Med Virol. 2023 Feb;95(2):e28430. doi: 10.1002/jmv.28430.
8
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals.使用和未使用COVID-19口服抗病毒药物时的SARS-CoV-2病毒反弹情况
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.
9
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis.奈玛特韦/利托那韦（Paxlovid）治疗 COVID-19 的疗效和安全性：快速评价和荟萃分析。
J Med Virol. 2023 Feb;95(2):e28441. doi: 10.1002/jmv.28441.
10
Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature.普克鲁胺治疗帕罗韦德治疗后 COVID-19 反弹：四例报告及文献复习。
J Clin Lab Anal. 2023 Apr;37(7):e24880. doi: 10.1002/jcla.24880. Epub 2023 Apr 23.
引用本文的文献
1
Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".新冠病毒感染使用奈玛特韦-利托那韦（帕罗韦德）治疗后寻求医疗护理的风险因素：“症状反弹”
Viruses. 2025 May 29;17(6):782. doi: 10.3390/v17060782.
2
Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir.使用瑞德西韦治疗后COVID-19症状反弹的发生率。
Infect Dis Rep. 2025 May 1;17(3):43. doi: 10.3390/idr17030043.
3
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.模型表明，奈玛特韦-利托那韦治疗后SARS-CoV-2的反弹是由靶细胞保留以及病毒清除不完全共同驱动的。
J Virol. 2025 Mar 18;99(3):e0162324. doi: 10.1128/jvi.01623-24. Epub 2025 Feb 4.
4
Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis.抗病毒药物和单克隆抗体治疗感染奥密克戎变异株的COVID-19患者的比较疗效：一项系统评价和网状Meta分析
Influenza Other Respir Viruses. 2024 Dec;18(12):e70065. doi: 10.1111/irv.70065.
5
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.模型显示，奈玛特韦-利托那韦治疗后SARS-CoV-2反弹是由靶细胞保留以及病毒清除不完全共同驱动的。
bioRxiv. 2024 Sep 16:2024.09.13.613000. doi: 10.1101/2024.09.13.613000.
6
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19.新冠病毒感染患者使用奈玛特韦/利托那韦治疗后的临床反弹。
BMC Infect Dis. 2024 Sep 12;24(1):963. doi: 10.1186/s12879-024-09842-8.
7
Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro.体外对易感细胞进行蛋白酶抑制剂处理后新冠病毒2型感染性形式的持续性
J Infect Dis. 2025 Feb 4;231(1):e68-e76. doi: 10.1093/infdis/jiae385.
8
COVID-19 clinical rebound after treatment with nirmatrelvir/ritonavir.使用奈玛特韦/利托那韦治疗后COVID-19的临床反弹。
Res Sq. 2024 Jun 21:rs.3.rs-4497916. doi: 10.21203/rs.3.rs-4497916/v1.
9
Viral SARS-CoV-2 Rebound Rates in Linked Commercial Pharmacy-Based Testing and Health Care Claims.基于连锁商业药房检测与医疗保健理赔数据的新型冠状病毒2型（SARS-CoV-2）病毒反弹率
Open Forum Infect Dis. 2024 May 2;11(6):ofae243. doi: 10.1093/ofid/ofae243. eCollection 2024 Jun.
10
SARS-CoV-2 infection rebound among patients receiving antiviral agents, convalescent plasma, or no treatment: a systematic review with meta-analysis.接受抗病毒药物、恢复期血浆或未接受治疗的患者中 SARS-CoV-2 感染复发：系统评价与荟萃分析。
Blood Transfus. 2024 Nov;22(6):537-550. doi: 10.2450/BloodTransfus.764. Epub 2024 May 27.
Zotero 插件